NASDAQ:EWTX Edgewise Therapeutics (EWTX) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free EWTX Stock Alerts $15.94 -0.17 (-1.06%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$15.08▼$15.9750-Day Range$15.08▼$18.5052-Week Range$5.12▼$20.69Volume607,514 shsAverage Volume500,279 shsMarket Capitalization$1.48 billionP/E RatioN/ADividend YieldN/APrice Target$31.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Edgewise Therapeutics alerts: Email Address Edgewise Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside95.7% Upside$31.20 Price TargetShort InterestBearish9.15% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 7 Articles This WeekInsider TradingSelling Shares$612,566 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.76) to ($1.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.59 out of 5 starsMedical Sector665th out of 908 stocksPharmaceutical Preparations Industry304th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingEdgewise Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEdgewise Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.15% of the float of Edgewise Therapeutics has been sold short.Short Interest Ratio / Days to CoverEdgewise Therapeutics has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Edgewise Therapeutics has recently increased by 0.70%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEdgewise Therapeutics does not currently pay a dividend.Dividend GrowthEdgewise Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EWTX. Previous Next 2.5 News and Social Media Coverage News SentimentEdgewise Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Edgewise Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 19 people have searched for EWTX on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Edgewise Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edgewise Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $612,566.00 in company stock.Percentage Held by Insiders31.95% of the stock of Edgewise Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Edgewise Therapeutics are expected to decrease in the coming year, from ($1.76) to ($1.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edgewise Therapeutics is -10.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Edgewise Therapeutics is -10.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEdgewise Therapeutics has a P/B Ratio of 3.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Edgewise Therapeutics Stock (NASDAQ:EWTX)Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Read More EWTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EWTX Stock News HeadlinesApril 23, 2024 | businesswire.comEdgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular DystrophiesApril 23, 2024 | americanbankingnews.comEdgewise Therapeutics (NASDAQ:EWTX) Price Target Increased to $32.00 by Analysts at Royal Bank of CanadaApril 26, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 23, 2024 | americanbankingnews.comEdgewise Therapeutics (NASDAQ:EWTX) Shares Gap Up Following Analyst UpgradeApril 22, 2024 | seekingalpha.comJANX Janux Therapeutics, Inc.April 19, 2024 | americanbankingnews.comEdgewise Therapeutics (NASDAQ:EWTX) Stock Rating Reaffirmed by Truist FinancialApril 17, 2024 | investing.comEdgewise reports positive Becker trial results, plans discussionApril 17, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Edgewise Therapeutics (EWTX) and Progyny (PGNY)April 26, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 17, 2024 | americanbankingnews.comEdgewise Therapeutics (NASDAQ:EWTX) Given "Outperform" Rating at WedbushApril 15, 2024 | businesswire.comEdgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)March 28, 2024 | businesswire.comEdgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific SessionMarch 27, 2024 | businesswire.comEdgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024March 5, 2024 | finance.yahoo.comEdgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024February 28, 2024 | businesswire.comEdgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific ConferenceFebruary 26, 2024 | finance.yahoo.comWall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should KnowFebruary 25, 2024 | investing.comEdgewise Therapeutics earnings missed by $0.04, revenue was in line with estimatesFebruary 24, 2024 | msn.comEdgewise Therapeutics (EWTX) Price Target Increased by 8.00% to 27.54February 22, 2024 | benzinga.comEdgewise Therapeutics Stock (NASDAQ:EWTX), Short Interest ReportFebruary 22, 2024 | benzinga.comEdgewise Therapeutics: Q4 Earnings InsightsFebruary 22, 2024 | msn.comEdgewise Therapeutics Non-GAAP EPS of $0.47February 22, 2024 | finance.yahoo.comEdgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsFebruary 22, 2024 | businesswire.comEdgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsFebruary 22, 2024 | investing.comEdgewise Therapeutics Inc (EWTX)February 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Edgewise Therapeutics (EWTX), Bicycle Therapeutics (BCYC)February 16, 2024 | finance.yahoo.comEWTX May 2024 30.000 callFebruary 13, 2024 | finance.yahoo.comEdgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)See More Headlines Receive EWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/26/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EWTX CUSIPN/A CIK1710072 Webwww.edgewisetx.com Phone720-262-7002FaxN/AEmployees88Year FoundedN/APrice Target and Rating Average Stock Price Target$31.20 High Stock Price Target$48.00 Low Stock Price Target$25.00 Potential Upside/Downside+95.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.06% Return on Assets-30.16% Debt Debt-to-Equity RatioN/A Current Ratio19.50 Quick Ratio19.50 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.53 per share Price / Book3.52Miscellaneous Outstanding Shares93,110,000Free Float63,362,000Market Cap$1.48 billion OptionableOptionable Beta0.14 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Peter A. Thompson FACP (Age 64)M.D., Co-Founder & Independent Chairman Comp: $73kDr. Kevin Koch Ph.D. (Age 64)President, CEO & Director Comp: $913.1kDr. Badreddin Edris Ph.D. (Age 36)Co-Founder & Independent Director Comp: $40kDr. Alan J. Russell Ph.D. (Age 54)Co-Founder, Chief Scientific Officer & Director Comp: $657.52kDr. Joanne M. Donovan M.D. (Age 67)Ph.D., Chief Medical Officer Comp: $695.48kMr. R. Michael Carruthers (Age 66)Chief Financial Officer Comp: $386.01kMr. John R. Moore (Age 60)General Counsel Dr. Behrad Derakhshan Ph.D. (Age 44)Chief Business Officer Comp: $575.53kDr. Marc Semigran M.D. (Age 67)Chief Development Officer More ExecutivesKey CompetitorsDay One BiopharmaceuticalsNASDAQ:DAWNAkero TherapeuticsNASDAQ:AKROMorphicNASDAQ:MORFArdelyxNASDAQ:ARDXKura OncologyNASDAQ:KURAView All CompetitorsInsiders & InstitutionsDenali Advisors LLCBought 19,200 shares on 4/19/2024Ownership: 0.021%Perceptive Advisors LLCBought 555,555 shares on 2/26/2024Ownership: 0.875%Virtu Financial LLCBought 24,037 shares on 2/26/2024Ownership: 0.038%Opaleye Management Inc.Sold 176,405 shares on 2/15/2024Ownership: 1.101%Parkman Healthcare Partners LLCBought 178,313 shares on 2/15/2024Ownership: 1.027%View All Insider TransactionsView All Institutional Transactions EWTX Stock Analysis - Frequently Asked Questions Should I buy or sell Edgewise Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edgewise Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EWTX shares. View EWTX analyst ratings or view top-rated stocks. What is Edgewise Therapeutics' stock price target for 2024? 5 Wall Street research analysts have issued twelve-month target prices for Edgewise Therapeutics' stock. Their EWTX share price targets range from $25.00 to $48.00. On average, they predict the company's share price to reach $31.20 in the next twelve months. This suggests a possible upside of 95.7% from the stock's current price. View analysts price targets for EWTX or view top-rated stocks among Wall Street analysts. How have EWTX shares performed in 2024? Edgewise Therapeutics' stock was trading at $10.94 at the beginning of the year. Since then, EWTX stock has increased by 45.7% and is now trading at $15.94. View the best growth stocks for 2024 here. Are investors shorting Edgewise Therapeutics? Edgewise Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,720,000 shares, an increase of 27.7% from the March 15th total of 4,480,000 shares. Based on an average trading volume of 1,010,000 shares, the days-to-cover ratio is presently 5.7 days. Approximately 9.1% of the shares of the company are short sold. View Edgewise Therapeutics' Short Interest. When is Edgewise Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our EWTX earnings forecast. How were Edgewise Therapeutics' earnings last quarter? Edgewise Therapeutics, Inc. (NASDAQ:EWTX) released its earnings results on Thursday, February, 22nd. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.03. What ETFs hold Edgewise Therapeutics' stock? ETFs with the largest weight of Edgewise Therapeutics (NASDAQ:EWTX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and ALPS Medical Breakthroughs ETF (SBIO).iShares U.S. Pharmaceuticals ETF (IHE). When did Edgewise Therapeutics IPO? Edgewise Therapeutics (EWTX) raised $150 million in an initial public offering on Friday, March 26th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow acted as the underwriters for the IPO. Who are Edgewise Therapeutics' major shareholders? Edgewise Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Denali Advisors LLC (0.02%). Insiders that own company stock include Alan J Russell, Behrad Derakhshan, Holdings A/S Novo, Joanne M Donovan, John R Moore, Jonathan C Fox, Kevin Koch, Orbimed Advisors Llc, Peter A Thompson and R Michael Carruthers. View institutional ownership trends. How do I buy shares of Edgewise Therapeutics? Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EWTX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
